Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C
Open Access
- 15 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (suppl_1), S16-S24
- https://doi.org/10.1093/cid/cis391
Abstract
Within the last year, the landscape of therapy for genotype 1 chronic hepatitis C virus (HCV) has changed dramatically as 2 much-anticipated protease inhibitors became available for use. These agents, telaprevir and boceprevir, when used in combination with pegylated interferon and ribavirin, offer patients an improved chance of cure and the opportunity for a shorter duration of therapy. Although these medications represent a significant achievement in the battle against HCV, they do not represent the final phase in the evolution of HCV therapy. Many other direct-acting antiviral agents representing several classes, as well as agents that act via host-mediated pathways, are in development. Recent proof of concept studies demonstrating the capacity to eradicate HCV without interferon signal the potential for yet another quantum leap in the field.Keywords
This publication has 36 references indexed in Scilit:
- Chronic Hepatitis C InfectionNew England Journal of Medicine, 2011
- Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus InfectionGastroenterology, 2011
- A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis CClinical Gastroenterology and Hepatology, 2011
- Outcome of sustained virological responders with histologically advanced chronic hepatitis CHepatology, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2bAnnals of Internal Medicine, 2009
- A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis CThe American Journal of Gastroenterology, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virusProceedings of the National Academy of Sciences of the United States of America, 1999